Retailleau Pascal, Colloc'h Nathalie, Vivarès Denis, Bonneté Françoise, Castro Bertrand, El Hajji Mohamed, Prangé Thierry
LURE, Centre Universitaire Paris-Sud, Bâtiment 209D, BP 34, 91898 Orsay CEDEX, France.
Acta Crystallogr D Biol Crystallogr. 2005 Mar;61(Pt 3):218-29. doi: 10.1107/S0907444904031531. Epub 2005 Feb 24.
Urate oxidase from Aspergillus flavus (uricase or Uox; EC 1.7.3.3) is a 135 kDa homotetramer with a subunit consisting of 301 amino acids. It catalyses the first step of the degradation of uric acid into allantoin. The structure of the extracted enzyme complexed with a purine-type inhibitor (8-azaxanthin) had been solved from high-resolution X-ray diffraction of I222 crystals. Expression of the recombinant enzyme in Saccharomyces cerevisiae followed by a new purification procedure allowed the crystallization of both unliganded and liganded enzymes utilizing the same conditions but in various crystal forms. Here, four different crystal forms of Uox are analyzed. The diversity of the Uox crystal forms appears to depend strongly on the chemicals used as inhibitors. In the presence of uracil and 5,6-diaminouracil crystals usually belong to the trigonal space group P3(1)21, the asymmetric unit (AU) of which contains one tetramer of Uox (four subunits). Chemical oxidation of 5,6-diaminouracil within the protein may occur, leading to the canonical (I222) packing with one subunit per AU. Coexistence of two crystal forms, P2(1) with two tetramers per AU and I222, was found in the same crystallization drop containing another inhibitor, guanine. Finally, a fourth form, P2(1)2(1)2 with one tetramer per AU, resulted fortuitously in the presence of cymelarsan, an additive. Of all the reported forms, the I222 crystal forms present by far the best X-ray diffraction resolution (approximately 1.6 angstroms resolution compared with 2.3-3.2 angstroms for the other forms). The various structures and contacts in all crystalline lattices are compared. The backbones are essentially conserved except for the region near the active site. Its location at the dimer interface is thus likely to be at the origin of the crystal contact changes as a response to the various bound inhibitors.
来自黄曲霉的尿酸氧化酶(尿酸酶或Uox;EC 1.7.3.3)是一种135 kDa的同四聚体,其亚基由301个氨基酸组成。它催化尿酸降解为尿囊素的第一步反应。通过I222晶体的高分辨率X射线衍射解析了与嘌呤型抑制剂(8-氮杂黄嘌呤)复合的提取酶的结构。在酿酒酵母中表达重组酶,随后采用新的纯化程序,使得未结合配体和结合配体的酶在相同条件下但以不同晶体形式结晶。在此,分析了Uox的四种不同晶体形式。Uox晶体形式的多样性似乎强烈依赖于用作抑制剂的化学物质。在尿嘧啶和5,6-二氨基尿嘧啶存在的情况下,晶体通常属于三方空间群P3(1)21,其不对称单元(AU)包含一个Uox四聚体(四个亚基)。蛋白质内5,6-二氨基尿嘧啶可能发生化学氧化,导致每个AU一个亚基的典型(I222)堆积。在含有另一种抑制剂鸟嘌呤的同一结晶液滴中发现了两种晶体形式的共存,即每个AU两个四聚体的P2(1)和I222。最后,在添加剂cymelarsan存在的情况下偶然得到了第四种形式,即每个AU一个四聚体的P2(1)2(1)2。在所有报道的形式中,I222晶体形式目前呈现出最佳的X射线衍射分辨率(约1.6埃分辨率,而其他形式为2.3 - 3.2埃)。比较了所有晶格中的各种结构和接触情况。除活性位点附近区域外,主链基本保守。因此,其在二聚体界面的位置可能是晶体接触变化的起源,这种变化是对各种结合抑制剂的响应。